Published in Support Care Cancer on August 24, 2002
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer (2005) 1.18
Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer (2002) 1.71
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol (2011) 1.99
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: a study from the Programma Ricerca e Innovazione Emilia Romagna Oncology Research Group. J Clin Oncol (2008) 1.46
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer (2006) 1.41
Cancer of the penis. Crit Rev Oncol Hematol (2005) 1.39
[Update on anticancer drugs]. Assist Inferm Ric (2014) 1.38
Germ cell tumours of the testis. Crit Rev Oncol Hematol (2005) 1.37
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer (2005) 1.36
Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes (2003) 1.34
Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer (2010) 1.26
XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer (2009) 1.17
Renal cancer. Crit Rev Oncol Hematol (2007) 0.96
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol (2009) 0.90
Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer (2004) 0.90
Prevalence and treatment of cancer pain in Italian oncological wards centres: a cross-sectional survey. Support Care Cancer (2008) 0.86
Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support Care Cancer (2010) 0.86
Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer (2004) 0.83
Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer (2010) 0.83
Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol (2013) 0.82
Treatment of lung cancer. N Engl J Med (2009) 0.82
Evidence-based recommendations for the use of antiemetics in radiotherapy. Radiother Oncol (2005) 0.82
Is there still a role for the uniscale assessment of quality of life? Tumori (2007) 0.82
[Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study]. Recenti Prog Med (2007) 0.81
The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants. Support Care Cancer (2004) 0.79
The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer (2006) 0.77
Cetuximab for colorectal cancer. N Engl J Med (2008) 0.75
Tackling off-label use of anticancer drugs. J Clin Oncol (2012) 0.75
Cetuximab for metastatic colorectal cancer. N Engl J Med (2009) 0.75
Multinational Association of Supportive Cancer Care (MASCC). Support Care Cancer (2003) 0.75
[Cancer-related fatigue]. Recenti Prog Med (2015) 0.75
Inappropriate doses of chemotherapy in Italian breast cancer patients enrolled in clinical trials. Tumori (2008) 0.75
Antiemetic therapy. Crit Rev Oncol Hematol (2002) 0.75
[Methodology of drug utilization studies]. Suppl Tumori (2004) 0.75
Surgical treatment of primitive thyroid lymphoma. Tumori (2010) 0.75